EN
We conduct and deliver high-quality clinical research on innovative drugs at all stages for various oncology indications, including but not limited to non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, prostate cancer, multiple myeloma, renal cancer, and hematology etc.
With the unique clinical resource advantages, we have established an early-stage oncology clinical research collaboration platform with seven research centers and reached strategic cooperation with hospitals such as the Department of Medical Oncology at the Fudan University Shanghai Cancer Center, Hunan Cancer Hospital, Shandong Cancer Institute, and more than 30 oncology Phase I sites; formed deep cooperation with hospitals such as Peking University Cancer Hospital, Blood Diseases Hospital of Chinese Academy of Medical Sciences, and Sun Yat-sen University Cancer Center; jointly established a Clinical Pharmacology Excellence Center with the First Affiliated Hospital of Bengbu Medical College, co-developed a clinical research-oriented hospital system, and expanded to over ten GCP alliance centers in the Jianghuai region. We have delivered nearly 200 oncology clinical trials.
We have top domestic autoimmune disease clinical research experts and research centers. We undertake drug clinical research projects in the field of autoimmune disorders, including psoriasis, rheumatoid arthritis, ankylosing spondylitis, moderate to severe dermatitis atopic, asthma, systemic lupus erythematosus, etc. Particularly in the field of immune-related diseases with long follow-up periods and complex and variable patient medication, we have accumulated extensive clinical research experience. We have delivered nearly 50 new drug clinical trials in the field of autoimmune disorders.
We possess experience and clinical resources in new drug clinical research projects in the field of infections, covering multiple infection-related sub-fields such as HPV, pulmonary tuberculosis, chronic hepatitis B, pneumonia, influenza viral infections, asthma, tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, urinary tract infection, skin infection, etc. We have delivered nearly 40 projects in the field of infections.
UnionClin reached a strategic cooperation with the National Medical Center for Infectious Diseases ("NMCID"). By leveraging the company's prioradvantageous experience in the field of oncology, UnionClin is helping NMCIDbuild a clinical research network in the field of infections. As a participating unit in the State Council's special group, the Department of Infectious Diseases of Huashan Hospital participates in the construction of clinical trial capacity in the field of national public health,leading the aggregation of over 40 leading PIs and more than 200 cooperativecenters nationwide to promote new drug development in the field of infectious diseases. At the same time, as a member of the WHO clinical trial platform, UnionClin plays an important role in advantageous research areas such as chronic viral hepatitis, tuberculosis, and respiratory tract infection, successfully filling multiple gaps in disease natural history and clinical epidemiological data knowledge and facilitating China's inclusion in the global tuberculosis innovative drug research and development system.
The disease treatment areas for which new drug clinical research can be conducted include cerebral stroke, Parkinson's disease, migraine, acute and chronic pain, stroke, Alzheimer's disease, autism, etc. We have established deep cooperation with leading clinical investigators and research centers in this field, and possess delivery experience of nearly 30 clinical trials on neurological disease drugs.
We have established deep cooperative relationships with domestic experts in the cardiovascular field, possess resources from leading clinical research centers; project experience involves hypertension, hyperlipidemia, chronic cardiac failure, arrhythmia, coronary heart disease, primary pulmonary arterial hypertension, etc. We have delivered nearly 30 cardiovascular projects.
Official WeChat
